Results 81 to 90 of about 60,957 (246)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

Cancer Management and Research, 2019
Jan Philipp Bewersdorf,1 Sara Mohamed Jaszczur,2 Salma Afifi,2 Jennifer C Zhao,2 Amer M Zeidan1,3 1Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; 2Department of Pharmacy, Yale New Haven Hospital, New ...
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM   +4 more
doaj  

Associations of CYLD, JAK2 and TLR4 Genotypes with PSA Levels and Immunophenotype in Benign Prostatic Hyperplasia and Prostate Cancer

Frontiers in Bioscience-Landmark
Background: Prostate cancer (PCa) is one of the most common malignant tumors of the male urinary system, and its incidence and mortality rates have been increasing worldwide.
Le Vu Duy, Pham Thi Huong, Nguyen Trung Nam, Do Thi Trang, Nghiem Thi Minh Chau, Tran Thi Phuong Thao, Nguyen Huy Hoang, Nguyen Thien Tao, Can Van Mao, Nguyen Thi Xuan   +9 more
doaj   +1 more source

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Less Jak2 makes more platelets [PDF]

Blood, 2014
In this issue of Blood , Meyer et al report that deleting Jak2 selectively in megakaryocytes and platelets results in an unexpected thrombocytosis phenotype. Their results demonstrate that Jak2 is dispensable for megakaryocyte differentiation and platelet formation but is required for suppressing circulating thrombopoietin (Tpo ...
openaire   +3 more sources

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Haematologica, 2013
JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies. Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated ...
Andrew Chase, Catherine Bryant, Joannah Score, Claudia Haferlach, Vera Grossmann, Juliana Schwaab, Wolf-Karsten Hofmann, Andreas Reiter, Nicholas C.P. Cross   +8 more
doaj   +1 more source

Isorhamnetin Alleviates Renal Fibrosis Induced by Renal Tubular Epithelial Cell Senescence Via Inhibition of the IL‐6/IL‐6R Signaling Pathway

iMetaMed, EarlyView.
IL‐6 from RTECs upregulates TGF‐β in macrophages, promoting fibroblast transdifferentiation. Isorhamnetin inhibits this effect. ABSTRACT Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease.
Weifei Liang, Xiangqiu Chen, Tao Wu, Xichun Zheng, Shaohua Zeng, Qingchun Zhou, Wen Ma, Hao Lin, Donglin Sun   +8 more
wiley   +1 more source

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

BMC Medical Genetics, 2012
Background Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms (MPNs) characterized in most cases by a unique somatic mutation, JAK2 V617F.
Ohyashiki Junko H, Yoneta Masayuki, Hisatomi Hisashi, Iwabuchi Tamiko, Umezu Tomohiro, Ohyashiki Kazuma   +5 more
doaj   +1 more source

Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer

iMetaMed, EarlyView.
The occurrence and progression of colorectal cancer are intricately linked to metabolites produced by the gut microbiota. Metabolites generated by pathogenic microbial communities can promote colorectal cancer development by reshaping the immune microenvironment.
Xinrui Yang, Ke Zhang, Lijie Xia, Jinyao Li   +3 more
wiley   +1 more source

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation

eLife, 2018
Cytokines and interferons initiate intracellular signaling via receptor dimerization and activation of Janus kinases (JAKs). How JAKs structurally respond to changes in receptor conformation induced by ligand binding is not known. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and ...
Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus   +2 more
openaire   +3 more sources